About 37 and 31 % diference in 3-year DFS and OS respectively were seen between patients with E2F1+TS+ colon cancer immunophenotype as compared to E2F1-TS- immunophenotype (Figs. 3 and 4). This evidence concerns the gene E2F1 and colonic neoplasm.